MetaCap

Kymera Therapeutics Inc. (KYMR)

NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

115.31-4.08 (-3.42%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KYMR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.64
52-week range
63.69 – 142.92
Day range
114.40 – 119.56
Volume / Avg
1.28M / 852.46K
Beta
—

52-week range

$63.69$142.92

KYMR stock today

Kymera Therapeutics (KYMR) closed at $115.31 on Nov 20, down 3.42% (-$4.08), versus the S&P 500's 3.70% decline. Shares are 19.3% below their 52-week high of $142.92, set on Nov 10, 2026 and 81.0% above the 52-week low of $63.69, in the middle of the past year's range. KYMR is up 48.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 74.6%.

Kymera Therapeutics has posted a net loss over the last twelve months (EPS of -$3.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kymera Therapeutics

Company profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Headquarters
Watertown, MA
Employees
285
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Kymera Therapeutics generated $39.2 million in revenue, down 16.7% from fiscal 2024, its first annual decline since 2024. Kymera Therapeutics reported a net loss of $311.4 million, compared with a loss of $223.9 million a year earlier. Gross margin was 0.0% (flat year over year) and operating margin -891.1%.

Kymera Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$39.21M$47.07M$78.59M$46.83M$72.83M
Growth-16.70%-40.11%+67.84%-35.71%+114.00%
Net income$-311.35M$-223.86M$-146.96M$-154.81M$-100.22M
EPS (diluted)$-3.69$-2.98$-2.52$-2.87$-2.09

Analyst forecast

Forecast

Consensus (24 analysts)

strong_buy

Avg. price target

$145.22+25.94%

  • Strong buy 5
  • Buy 17
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $116.00High $180.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-1.32 vs $-1.26
Surprise
-4.76%

KYMR news

All KYMR news

Kymera Therapeutics peers

Health Care sector
KYMR peer companies
CompanyPrice% ChgMarket capCompare
QGENQiagen N.V.49.30-0.66%$10.18Bvs KYMR
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs KYMR
RGENRepligen Corporation163.81-3.81%$10.47Bvs KYMR
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs KYMR
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs KYMR
TECHBio-Techne Corp72.67-0.04%$11.42Bvs KYMR
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs KYMR
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs KYMR

Indexes, lists and sector

Kymera Therapeutics stock FAQ

What is Kymera Therapeutics's stock price today?

KYMR last traded at $115.31 as of Nov 20, 4:00 PM EST, down 3.42% on the day. Prices are delayed at least 15 minutes.

Who is Kymera Therapeutics's CEO?

Dr. Nello Mainolfi M.D., Ph.D. is the chief executive officer of Kymera Therapeutics Inc., which has about 285 employees.

What is the KYMR 52-week high?

The 52-week high for KYMR is $142.92 and the 52-week low is $63.69. The stock is currently 19.3% below its high.

Compare KYMR